Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

982 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addressing racial disparities in prostate cancer pathology prediction models: external validation and comparison of four models of pathological outcome prediction before radical prostatectomy in the multiethnic SEARCH cohort.
Mottaghi M, Gu L, Deivasigamani S, Adams ES, Parrish J, Amling CL, Aronson WJ, Kane CJ, Terris MK, Guerrios-Rivera L, Cooperberg MR, Klaassen Z, Freedland SJ, Polascik TJ. Mottaghi M, et al. Among authors: kane cj. Prostate Cancer Prostatic Dis. 2024 Apr 11. doi: 10.1038/s41391-024-00830-2. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38605270
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. Rodriguez-Otero P, et al. Among authors: kane c. Blood Cancer J. 2024 Mar 6;14(1):40. doi: 10.1038/s41408-024-01018-6. Blood Cancer J. 2024. PMID: 38448422 Free PMC article. No abstract available.
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. Rodriguez-Otero P, et al. Among authors: kane c. Blood Cancer J. 2024 Feb 2;14(1):24. doi: 10.1038/s41408-023-00966-9. Blood Cancer J. 2024. PMID: 38307865 Free PMC article. Review.
A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy.
Lerner A, Lee AJX, Yan H, Van Griethuysen J, Bartlett AD, Veli M, Jiang Y, Luong M, Naban N, Kane C, Conibear J, Papadatos-Pastos D, Ahmad T, Chao D, Anand G, Asghar US. Lerner A, et al. Among authors: kane c. Clin Oncol (R Coll Radiol). 2024 Mar;36(3):193-199. doi: 10.1016/j.clon.2024.01.009. Epub 2024 Jan 16. Clin Oncol (R Coll Radiol). 2024. PMID: 38246850
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
McKay RR, Xie W, Yang X, Acosta A, Rathkopf D, Laudone VP, Bubley GJ, Einstein DJ, Chang P, Wagner AA, Kane CJ, Preston MA, Kilbridge K, Chang SL, Choudhury AD, Pomerantz MM, Trinh QD, Kibel AS, Taplin ME. McKay RR, et al. Among authors: kane cj. Cancer. 2024 May 1;130(9):1629-1641. doi: 10.1002/cncr.35170. Epub 2024 Jan 1. Cancer. 2024. PMID: 38161319 Clinical Trial.
m-PIMA™ HIV1/2 VL: A suitable tool for HIV-1 and HIV-2 viral load quantification in West Africa.
Diop-Ndiaye H, Sène PY, Coulibaly K, Diallo M, Diallo S, Diop K, Sow-Ndoye A, Fall M, Ndiaye AJS, Mathebula E, Ba AA, Lejeune C, Manga NMP, Camara M, Ndour CT, Kane CT. Diop-Ndiaye H, et al. Among authors: kane ct. J Virol Methods. 2024 Feb;324:114872. doi: 10.1016/j.jviromet.2023.114872. Epub 2023 Dec 19. J Virol Methods. 2024. PMID: 38128833 Free article.
982 results